



# Review decision – July 2018

Review decision

Published: 6 July 2018

[www.nice.org.uk](http://www.nice.org.uk)

## Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA340; Ustekinumab for treating active psoriatic arthritis.

No new evidence is available that would require an update of this guidance. The guidance has been incorporated into the NICE guideline on [spondyloarthritis in over 16s: diagnosis and management](#) (NG65).

NICE's Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA340 will move to the 'static list' of technology appraisals.

[Review decision paper](#)